<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812262</url>
  </required_header>
  <id_info>
    <org_study_id>DD01-DN-1</org_study_id>
    <nct_id>NCT04812262</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuraly, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuraly, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single&#xD;
      ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety,&#xD;
      tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in&#xD;
      overweight/obese subjects with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease&#xD;
      (NAFLD).&#xD;
&#xD;
      The study will be conducted in 2 Parts (Part A and B), with up to 4 cohorts included in each&#xD;
      part (Part A; Cohorts A1 to A4 and Part B; Cohorts B1 to B4).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A (SAD):&#xD;
&#xD;
      In Part A, subjects will receive a single dose of study drug, and the safety and efficacy of&#xD;
      DD01 will be evaluated in overweight/obese subjects with T2DM.&#xD;
&#xD;
      Part B (MAD):&#xD;
&#xD;
      In Part B, subjects will receive once-weekly doses of the study drug for 4 weeks, and the&#xD;
      safety and efficacy of DD01 will be evaluated in overweight/obese subjects with T2DM and&#xD;
      NAFLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A - Cohorts A1, A2, A3 and A4 Part B - Cohorts B1, B2, B3 and B4</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events and serious adverse events</measure>
    <time_frame>Part A - 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events and serious adverse events (TEAEs)</measure>
    <time_frame>Part B - 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in clinical laboratory values</measure>
    <time_frame>Part A - 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in clinical laboratory values</measure>
    <time_frame>Part B - 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in physical examinations</measure>
    <time_frame>Part A - 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in physical examinations</measure>
    <time_frame>Part B - 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in vital signs</measure>
    <time_frame>Part A - 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in vital signs</measure>
    <time_frame>Part B - 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>Part A - 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>Part B - 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader)</measure>
    <time_frame>Part A - 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader)</measure>
    <time_frame>Part B - 57 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in 12-lead ECGs</measure>
    <time_frame>Part A - 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant abnormalities in 12-lead ECGs</measure>
    <time_frame>Part B - 57 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed blood/plasma concentration of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Maximum observed blood/plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed blood/plasma concentration of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Maximum observed blood/plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum observed blood/plasma concentration of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Time of the maximum observed blood/plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum observed blood/plasma concentration of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Time of the maximum observed blood/plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent blood/plasma terminal elimination half life of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Apparent blood/plasma terminal elimination half life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent blood/plasma terminal elimination half life of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Apparent blood/plasma terminal elimination half life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Termination elimination rate constant of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Termination elimination rate constant (kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Termination elimination rate constant of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Termination elimination rate constant (kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total blood/plasma clearance of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Apparent total blood/plasma clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total blood/plasma clearance of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Apparent total blood/plasma clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Apparent volume of distribution(Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Apparent volume of distribution(Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood/plasma concentration time curve from time zero to the time of the last quantifiable concentration of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Area under the blood/plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood/plasma concentration time curve from time zero to the time of the last quantifiable concentration of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Area under the blood/plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood/plasma concentration time curve from time zero to 144 hours postdose of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Area under the blood/plasma concentration time curve from time zero to 144 hours postdose (AUC0-144)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood/plasma concentration time curve from time zero to 144 hours postdose of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Area under the blood/plasma concentration time curve from time zero to 144 hours postdose (AUC0-144)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood/plasma concentration time curve from time zero to 216 hours postdose of DD01</measure>
    <time_frame>Part A - 43 days</time_frame>
    <description>Area under the blood/plasma concentration time curve from time zero to 216 hours postdose (AUC0-216)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood/plasma concentration time curve from time zero to 216 hours postdose of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Area under the blood/plasma concentration time curve from time zero to 216 hours postdose (AUC0-216)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the blood/plasma concentration time curve from time zero to 168 hours postdose of DD01</measure>
    <time_frame>Part B - 57 days</time_frame>
    <description>Part B only: Area under the blood/plasma concentration time curve from time zero to 168 hours postdose (AUC0-168)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with antidrug antibodies (ADAs)</measure>
    <time_frame>Part A - 43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with antidrug antibodies (ADAs)</measure>
    <time_frame>Part B - 57 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Overweight and Obesity</condition>
  <condition>Type2 Diabetes</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Group A1 - Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2, Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A3, Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A4, Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B1 - Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 1 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B2 - Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 2 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B3 - Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 3 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B4 - Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DD01 Dose 4 (N=6) Placebo (N=2) Subcutaneous injection once weekly for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DD01</intervention_name>
    <description>The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.</description>
    <arm_group_label>Group A1 - Single Ascending Dose</arm_group_label>
    <arm_group_label>Group A2, Single Ascending Dose</arm_group_label>
    <arm_group_label>Group A3, Single Ascending Dose</arm_group_label>
    <arm_group_label>Group A4, Single Ascending Dose</arm_group_label>
    <arm_group_label>Group B1 - Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Group B2 - Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Group B3 - Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Group B4 - Multiple Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug of DD01, administered in a 1mL volume for injection</description>
    <arm_group_label>Group A1 - Single Ascending Dose</arm_group_label>
    <arm_group_label>Group A2, Single Ascending Dose</arm_group_label>
    <arm_group_label>Group A3, Single Ascending Dose</arm_group_label>
    <arm_group_label>Group A4, Single Ascending Dose</arm_group_label>
    <arm_group_label>Group B1 - Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Group B2 - Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Group B3 - Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Group B4 - Multiple Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes ≥ 12 months.&#xD;
&#xD;
          -  Treatment with diet and exercise or metformin monotherapy on stable dose for 3 months&#xD;
             prior to screening&#xD;
&#xD;
          -  HbA1c ≤ 10%).&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 25 and ≤ 40.0 kg/m2&#xD;
&#xD;
        Part B Inclusion Criteria&#xD;
&#xD;
          -  Type 2 diabetes ≥ 12 months.&#xD;
&#xD;
          -  Treatment with diet and exercise or metformin monotherapy on stable dose for 3 months&#xD;
             prior to screening&#xD;
&#xD;
          -  HbA1c ≤ 10%&#xD;
&#xD;
          -  BMI ≥ 30 kg/m2 and ≤ 40.0 kg/m2&#xD;
&#xD;
          -  Waist circumference ≤ 57 inches&#xD;
&#xD;
          -  Controlled attenuation parameter by FibroScan&#xD;
&#xD;
          -  Liver fat fraction ≥ 10% by magnetic resonance imaging (MRI)&#xD;
&#xD;
        Part A Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes mellitus (T1DM)&#xD;
&#xD;
          -  History of acute proliferative retinopathy or maculopathy, severe gastroparesis,&#xD;
             and/or severe neuropathy, in particular autonomic neuropathy, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Treatment with antihypertensive medication and statins not stable during the past 2&#xD;
             months prior to screening&#xD;
&#xD;
          -  Treatment with thyroid hormones not stable during the past 3 months prior to screening&#xD;
&#xD;
          -  History of any weight control treatment, including over-the-counter and herbal&#xD;
             medication and supplements, or any medication with a labeled indication for weight&#xD;
             loss or weight gain within 3 months prior to screening&#xD;
&#xD;
          -  History of surgical treatment for obesity&#xD;
&#xD;
          -  History of heart disease&#xD;
&#xD;
          -  History of renal disease&#xD;
&#xD;
          -  History or current diagnosis of acute or chronic pancreatitis or factors for&#xD;
             pancreatitis, such as a history of cholelithiasis (without cholecystectomy) or alcohol&#xD;
             abuse&#xD;
&#xD;
          -  A history of or active chronic liver disease due to alcohol, auto-immune, HIV, HBV or&#xD;
             active HCV-infection or NASH&#xD;
&#xD;
          -  History of major depression, anxiety, suicidal behavior or attempts, or other&#xD;
             psychiatric disorder requiring medical treatment&#xD;
&#xD;
          -  Personal or family history of medullary thyroid carcinoma (MTC) or a genetic condition&#xD;
             that predispose to MTC (i.e., multiple endocrine neoplasia type 2)&#xD;
&#xD;
          -  Administration of Vaccines/Immunizations within 14 days prior to first dosing or if&#xD;
             scheduled during the study. Vaccination for COVID-19 is allowed during the study if a&#xD;
             washout period of 5 days after vaccine administration is followed before dosing.&#xD;
&#xD;
          -  History of any major surgery within 6 months prior to screening&#xD;
&#xD;
          -  Participation in any other clinical interventional study receiving active treatment&#xD;
             within 30 days or 5 half-lives prior to screening, whichever is longer&#xD;
&#xD;
          -  History of alcohol or illicit drug abuse including marijuana&#xD;
&#xD;
          -  Existence of any surgical or medical condition that, in the judgment of the&#xD;
             Investigator, might interfere with the investigational product&#xD;
&#xD;
        PART B Exclusion Criteria&#xD;
&#xD;
          -  History of type 1 diabetes mellitus (T1DM)&#xD;
&#xD;
          -  History of acute proliferative retinopathy or maculopathy, severe gastroparesis,&#xD;
             and/or severe neuropathy, in particular autonomic neuropathy, as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Uncontrolled hypertension (treatment with medications must be stable)&#xD;
&#xD;
          -  History of any weight control treatment&#xD;
&#xD;
          -  History of surgical treatment for obesity&#xD;
&#xD;
          -  History of heart disease&#xD;
&#xD;
          -  History of renal disease&#xD;
&#xD;
          -  Subjects with a history or clinically significant active disease of the&#xD;
             gastrointestinal, cardiovascular, hepatic, neurological, renal, pancreatic,&#xD;
             immunological, dermatological, endocrine, genitourinary or hematological system.&#xD;
&#xD;
          -  History or current diagnosis of acute or chronic pancreatitis&#xD;
&#xD;
          -  History of major depression, anxiety, suicidal behavior or attempts, or other&#xD;
             psychiatric disorder requiring medical treatment&#xD;
&#xD;
          -  History of alcohol or illicit drug abuse including marijuana&#xD;
&#xD;
          -  Existence of any surgical or medical condition that, in the judgment of the&#xD;
             Investigator, might interfere with the investigational product&#xD;
&#xD;
          -  Any history of clinically significant chronic liver disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prosciento</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Rodriguez</last_name>
      <phone>619-799-4818</phone>
      <email>robyn.rodriguez@prosciento.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest General Healthcare Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Warnsky</last_name>
      <phone>407-476-0514</phone>
      <email>brian.swghcc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose E Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Combined Research Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yenilady Estevez</last_name>
      <phone>407-440-4493</phone>
      <email>yenilady@clinicaltrialsorlando.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FDI Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Digmarie Rivera</last_name>
      <phone>787-722-1248</phone>
      <email>drivera@fdipr.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

